EBetween November 7 and 14, 2024, the National Agency for the Safety of Medicines and Health Products (ANSM) reported new disruptions or updated the availability data for several specialties marketed in France [1]distributed exclusively to the hospital.
ETOPOSIDE ACCORD: the rupture extends to the 10 mL vial
ETOPOSIDE ACCORD 20 mg/mL concentrate for infusion in vials of 10 mL, 25 mL and 50 mL (etoposide)
Availability status according to ANSM
- Out of stock for presentations in 10 mL, 25 mL and 50 mL bottles (cf. our article of October 3, 2024)
- The Teva laboratory provides repairs in 50 mL bottles up to the usual needs
- Normal availability of the presentation in a 50 mL bottle mid-December 2024
- Normal availability of the presentation in a 25 mL bottle mid-December 2024
- Normal availability of the presentation in 10 mL bottle undetermined
FLUOROURACILE AGREEMENT: situation as of November 14, 2024
FLUOROURACIL ACCORD 50 mg/mL concentrate for solution for infusion (fluorouracil)
Availability status according to ANSM
TIBERAL injectable: availability date postponed
TIBERAL 500 mg solution pour perfusion (ornidazole)
Availability status according to ANSM
Additional information from the laboratory
Letter from the laboratory to health professionals (August 12, 2024)
Specialties returned to normal availability
The ANSM has confirmed the normal availability of the following specialties:
Related News :